MENU

HX1 LNPs: Rational Design for Brain Delivery of RNA Therapeutics

Nature Nanotechnology
Overview
Researchers have developed HX1 lipid nanoparticles (LNPs) using a hydroxyzine-based scaffold to overcome central nervous system (CNS) barriers. The platform enables efficient mRNA delivery and gene editing in mouse and non-human primate brains, demonstrating potential for treating radiation-induced brain injury.
In Depth

Key Findings

The development of HX1 lipid nanoparticles (LNPs) provides a translational platform for delivering therapeutic mRNAs and genome-editing components to the brain. In mouse models, HX1 LNPs achieved robust mRNA delivery and enabled efficient gene editing through the co-delivery of CRISPR mRNA and guide RNA. Furthermore, the platform successfully delivered luciferase mRNA to the brains of non-human primates.

Technical Details

To identify molecular scaffolds capable of crossing CNS barriers, researchers analyzed the pharmaceutical profiles of over 100 CNS-active drugs. This analysis identified hydroxyzine (HX) as a promising scaffold for the design of ionizable lipids with enhanced brain-targeting properties. The resulting HX1 LNPs utilize multiple trafficking pathways to navigate across CNS barriers. In a therapeutic application, HX1 LNPs carrying Il10 mRNA were shown to mitigate radiation-induced brain injury in mice, proving effective even in the presence of intact CNS barriers.

Background & Context

Effective delivery of RNA therapeutics to the brain is historically challenging due to the multiple biological barriers inherent to the central nervous system. While various nanoparticulate RNA delivery systems and lipid nanoparticles have been explored for mRNA stability and regeneration therapy, achieving precise brain targeting remains a critical hurdle in the field of nucleic acid therapeutics.

Significance & Outlook

The ability of HX1 LNPs to deliver genetic material across intact CNS barriers suggests a significant advancement for preventive and therapeutic treatments. By leveraging a scaffold derived from a known CNS-active drug, this rational design approach establishes a viable pathway for the delivery of complex payloads, including CRISPR components, to the brain in both rodent and primate models.

Source: https://doi.org/10.1038/s41565-026-02326-7

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC